Predictive Oncology Inc. (NASDAQ:POAI) said it has appointed Dr Robert F. Murphy, a pioneer in the field of machine learning and analytics for biological data, to its scientific advisory board.
Dr Murphy is an expert in developing algorithms and models and was the founding head of the Computational Biology Department at Carnegie Mellon University (CMU).
He led the development of CORE, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform, the company noted.
Predictive Oncology says it is changing the landscape of cancer drug discovery. By pairing the machine learning of CORE with a biobank of more than 150K tumor samples, it has developed a solution with its PEDAL platform that can improve the probability of success for biopharma partners.
READ: Predictive Oncology adds Chan Zuckerberg Initiative's Marc Malandro to its scientific advisory board
"I am committed to the mission and the impact we can have in advancing the development of therapies that are more effective at fighting cancer," said Dr Murphy in a statement.
"Because of the continuous iterative development of complex predictive models and the power that generating data against a diverse patient population provides to evaluating a given therapy, Predictive Oncology has the ability to advance molecules to medicine with better confidence," he added.
Raymond F. Vennare, Predictive Oncology's CEO, told investors: "Dr. Murphy brings a depth of knowledge that allows us to expand the boundaries of scientific research and how we can use our technology and domain expertise to generate proprietary data for our partners."
Dr Murphy has also served at CMU as Professor of Biological Sciences, Biomedical Engineering, and Machine Learning.
He is an Honorary Professor of Biology at the Albert Ludwig University of Freiburg, Germany, and was the recipient of an Alexander von Humboldt Foundation Senior Research Award.
He also holds a patent for identifying location biomarkers, published more than 200 research papers and served on numerous editorial boards, committees, advisory panels, conference organizations and committee panels.
Contact the author at giles@proactiveinvestors.com